Physician profile
Joseph Ortiz
NPI 1235126624
$2,944.39
in general payments reported to CMS, 2019-2025
20 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $387 · 2021: $143 · 2022: $361 · 2023: $152 · 2024: $536 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $484.10 | 2022-2025 | Tryptyr, Clareon, Rocklatan |
| Abbvie INC. | $374.69 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $356.18 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $350.23 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $313.99 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $194.71 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ani Pharmaceuticals, INC. | $126.21 | 2025 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $111.29 | 2019 | |
| Dompe US, INC. | $97.42 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $91.43 | 2021-2022 | |
| Thea Pharma INC. | $68.39 | 2023-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $66.09 | 2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.69 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $50.12 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $43.47 | 2023-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.03 | 2019 | |
| Shire North American Group INC | $42.39 | 2019 | |
| Eyevance Pharmaceuticals LLC | $40.35 | 2019-2022 | |
| Harrow Eye, LLC | $19.25 | 2024 | Vevye |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.36 | 2023 | Xifaxan, Plenvu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.